

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Operations
(UNAUDITED)

| | For the year ended May 31, | | October 28, 2003 (Inception) through May 31, 2008 |
|--|---------------------------------------|----------------|--|
| | 2008 | 2007 | |
| Operating expenses: | | | |
| General and administrative | \$ 464,206 | \$ 1,619,462 | \$ 4,198,884 |
| Amortization / Depreciation..... | 2,162 | 168,184 | 174,322 |
| Research and Development..... | 145,067 | 424,739 | 932,148 |
| Legal Fees | 182,474 | 252,745 | 651,969 |
| Total operating expenses..... | 793,909 | 2,465,130 | 5,957,323 |
| Operating loss..... | (793,909) | (2,465,130) | (5,957,323) |
| Interest income..... | | (949) | (1,627) |
| Interest expense: | | | |
| Interest on convertible debt and other notes | | 145,889 | 617,354 |
| Loss before income taxes..... | (793,909) | (2,610,070) | (6,573,050) |
| Income tax provision | — | — | - |
| Net loss..... | \$ (793,909) | \$ (2,610,070) | \$ (6,573,050) |
| Basic and diluted loss per share..... | \$ (0.07) | \$ (0.24) | \$ (0.57) |
| Basic and diluted weighted average common shares outstanding..... | 11,468,164 | 10,997,063 | 11,468,164 |